Content
All Posts > Content under Pharma/Biotech
RMTI Announces FDA Committee Review Of Triferic; HZNP Presents Results Of ACTIMMUNE(R)
Article By:
BioMedReports
Read
Friday, October 10, 2014 6:50 AM EDT
Rockwell Medical, Inc. a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services. Horizon Pharma plc announced the presentation of data from a Phase 2 clinical study of ACTIMMUNE
CVS - Chart Of The Day
Article By:
Jim Van Meerten
Read
Friday, October 10, 2014 3:48 AM EDT
CVS Health Corporation is a pharmacy innovation company. The Trend Spotter signaled a new buy on 10/3 and the stock is up .76%.
In this article: CVS
AMGN Declares A Head-to-Head Phase III; CNAT Reports Acceptance Of Abstract For AASLD Meeting
Article By:
BioMedReports
Read
Thursday, October 9, 2014 9:56 AM EDT
Amgen (AMGN) has claimed gaining regulatory approval for its biosimilar of Humira, AbbVie's (ABBV) mega blockbuster anti-inflammatory drug.
RNN New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine, And Cisplatin
Article By:
BioMedReports
Read
Thursday, October 9, 2014 3:03 AM EDT
Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform, might one day join the leagueof bigger players.
TransTech Digest: Age Evasion Or Compression Of Morbidity
Article By:
Patrick Cox
Read
Wednesday, October 8, 2014 6:26 PM EDT
Last week, an FDA committee voted 20 to 1 to make it more difficult for doctors to prescribe testosterone products. The committee also recommended that pharmaceutical companies be forced to perform additional safety testing.
OXiGENE: First Patient Enrolled In Phase 1b/2 Study Of Fosbretabulin
Article By:
Trevor Lowenthal
Read
Wednesday, October 8, 2014 12:04 PM EDT
OXiGENE announces that the first patient has been enrolled in the Phase 1b/2 study of fosbretabulin in combination with Votrient(TM) (pazopanib) in patients with recurrent ovarian cancer.
In this article: OXGN
Chimerix - Chart Of The Day
Article By:
Jim Van Meerten
Read
Wednesday, October 8, 2014 4:33 AM EDT
Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs.
In this article: CMRX
BMY Withdraws NDA On Asunaprevir In The US; BCRX Reports On OPuS-1 Phase 2 Trial Results
Article By:
BioMedReports
Read
Wednesday, October 8, 2014 3:11 AM EDT
Bristol-Myers Squibb has decided that it will not pursue FDA approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States.BioCryst Pharmaceuticals, Inc. announced results from its successful OPuS-1 (Oral ProphylaxiS-1).
RXi Pharmaceuticals Posts Positive Phase 2a 3-Month Results In Hypertrophic Scars
Article By:
Terry Chrisomalis
Read
Tuesday, October 7, 2014 3:13 PM EDT
This validation is important because now the company is at a reduced risk investment level.
Biotech Investors Gamble On Ebola Stocks
Article By:
BioMedReports
Read
Tuesday, October 7, 2014 6:39 AM EDT
The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA’s awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more than constant media attention.
Healthcare Review: PTCT, HLF ALQA, ARIA, ADHD
Article By:
BioMedReports
Read
Monday, October 6, 2014 5:24 PM EDT
Global equity markets extended a rally on Monday that drew strength from a forecast-beating U.S. jobs report last week that bolstered confidence in the American economy and the Federal Reserve's monetary policy, but the dollar gave up some of its gains.
Why We Allow Big Pharma To Rip Us Off
Article By:
Robert Reich
Read
Monday, October 6, 2014 3:33 AM EDT
According to a new federal database put online last week, pharmaceutical companies and device makers paid doctors some $380 million in speaking and consulting fees over a five-month period in 2013.
